GENFIT-ADR (GNFT) Stock Fundamental Analysis
NASDAQ:GNFT - Nasdaq - US3722791098 - ADR - Currency: USD
Overall GNFT gets a fundamental rating of 4 out of 10. We evaluated GNFT against 557 industry peers in the Biotechnology industry. GNFT has a medium profitability rating, but doesn't score so well on its financial health evaluation. GNFT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GNFT was profitable.
In the past year GNFT had a positive cash flow from operations.
In multiple years GNFT reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 1.00%, GNFT belongs to the best of the industry, outperforming 90.66% of the companies in the same industry.
With an excellent Return On Equity value of 2.18%, GNFT belongs to the best of the industry, outperforming 91.74% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.45%, GNFT belongs to the top of the industry, outperforming 92.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROIC | 3.45% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of GNFT (2.12%) is better than 91.20% of its industry peers.
In the last couple of years the Profit Margin of GNFT has declined.
GNFT has a Operating Margin of 4.55%. This is amongst the best in the industry. GNFT outperforms 92.64% of its industry peers.
GNFT's Operating Margin has declined in the last couple of years.
GNFT's Gross Margin of 97.11% is amongst the best of the industry. GNFT outperforms 97.49% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GNFT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
GNFT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.76, we must say that GNFT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.76, GNFT perfoms like the industry average, outperforming 53.68% of the companies in the same industry.
The Debt to FCF ratio of GNFT is 4.26, which is a neutral value as it means it would take GNFT, 4.26 years of fcf income to pay off all of its debts.
GNFT's Debt to FCF ratio of 4.26 is amongst the best of the industry. GNFT outperforms 93.54% of its industry peers.
GNFT has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
GNFT has a Debt to Equity ratio of 0.08. This is in the lower half of the industry: GNFT underperforms 63.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | -1.76 |
ROIC/WACC0.46
WACC7.51%
2.3 Liquidity
A Current Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
GNFT's Current ratio of 1.23 is on the low side compared to the rest of the industry. GNFT is outperformed by 84.38% of its industry peers.
A Quick Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
GNFT has a worse Quick ratio (1.23) than 83.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
GNFT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.17%, which is quite impressive.
GNFT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -70.77% yearly.
GNFT shows a strong growth in Revenue. In the last year, the Revenue has grown by 85.82%.
Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
3.2 Future
GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -45.31% yearly.
The Revenue is expected to decrease by -1.99% on average over the next years.
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GNFT is valuated quite expensively with a Price/Earnings ratio of 91.25.
Based on the Price/Earnings ratio, GNFT is valued cheaper than 91.38% of the companies in the same industry.
GNFT is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
GNFT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.25 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GNFT is valued cheaper than 93.36% of the companies in the same industry.
96.59% of the companies in the same industry are more expensive than GNFT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.7 | ||
| EV/EBITDA | 28.39 |
4.3 Compensation for Growth
GNFT has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -45.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:GNFT (7/11/2025, 8:18:57 PM)
3.65
-0.1 (-2.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap182.51M
Analysts90.77
Price Target11.26 (208.49%)
Short Float %0.09%
Short Ratio4.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.91%
PT rev (3m)10%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.12%
EPS NY rev (3m)89.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)117.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.25 | ||
| Fwd PE | N/A | ||
| P/S | 2.2 | ||
| P/FCF | 10.7 | ||
| P/OCF | 10.02 | ||
| P/B | 2.25 | ||
| P/tB | 7.34 | ||
| EV/EBITDA | 28.39 |
EPS(TTM)0.04
EY1.1%
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.34
FCFY9.35%
OCF(TTM)0.36
OCFY9.98%
SpS1.66
BVpS1.62
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROCE | 4.23% | ||
| ROIC | 3.45% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% | ||
| FCFM | 20.54% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 1.12 | ||
| Cap/Depr | 56.79% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 314.19% | ||
| Profit Quality | 966.82% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -1.76 |
F-Score7
WACC7.51%
ROIC/WACC0.46
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.99%
EBIT growth 1Y112.1%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y125.16%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y128.05%
OCF growth 3Y-46.21%
OCF growth 5YN/A